Samsung Biologics Reports First Quarter 2026 Financial Results [TheStreet.com]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: TheStreet.com
INCHEON, South Korea, April 22, 2026 Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion Performance driven by full utilization across Plants 1 through 4 and robust operational execution Strengthened the foundations for future growth through U.S. expansion and strategic partnerships INCHEON, South Korea April 22, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026. "In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand from clients," said John Rim, President and CEO of Samsung Biologics. "With full operations in plants at our Bio Campus I and Plant 5 ramp-up underway, we are further strengthening manufacturing readiness and service capacity to support evolving client needs. As our global footprint contin
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) had its price target raised by Guggenheim from $1,163.00 to $1,183.00. They now have a "buy" rating on the stock.MarketBeat
- Novo Nordisk: Is The GLP-1 Golden Age Already Behind It? [Seeking Alpha]Seeking Alpha
- Neuroblastoma Treatment Market Analysis Report 2025-2035 - Regional Players and Local Manufacturers are Expected to Play an Important Role in Future Growth [Yahoo! Finance]Yahoo! Finance
- Here is why Eli Lilly (LLY) is Among the 8 Best Beginner Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- LLY's page on the SEC website